Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,718.06
(
0.28%
)
US TECH 100
24,131.20
(
0.48%
)
Dow Jones
47,042.51
(
0.20%
)
Brent Oil
100.87
(
2.61%
)
Bitcoin
74,677.67
(
-0.22%
)
News Focus
News Focus
Post# of 257252
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122792
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ThomasS post# 59235

Monday, 02/18/2008 2:57:40 AM

Monday, February 18, 2008 2:57:40 AM

Post# of 257252
>A poster on another Board (RPRX, naturally) mentioned that MNTA would never be able to get around Teva's patent, totally ignoring that Sanofi's Lovenox patent is, in all likelihood, being negated as we speak by Teva!<

It’s astonishing that someone can be so clueless about the pharma business. The fact is: nearly every big-selling non-biologic drug has already had its patent challenged or soon will. Moreover, the KSR decision by the US Supreme Court makes it considerably easier for a challenger to prevail (#msg-19404785).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now